Mining Nucleic Acid "omics" to Boost Liquid Biopsy in Cancer

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2024 Sep 18

PMID 39293399

Authors

Ann Tivey

Rebecca J Lee

Alexandra Clipson

Steven M Hill

Paul Lorigan

Dominic G Rothwell

Caroline Dive

Florent Mouliere

Affiliations

Soon will be listed here.

Abstract

Treatments for cancer patients are becoming increasingly complex, and there is a growing desire from clinicians and patients for biomarkers that can account for this complexity to support informed decisions about clinical care. To achieve precision medicine, the new generation of biomarkers must reflect the spatial and temporal heterogeneity of cancer biology both between patients and within an individual patient. Mining the different layers of 'omics in a multi-modal way from a minimally invasive, easily repeatable, liquid biopsy has increasing potential in a range of clinical applications, and for improving our understanding of treatment response and resistance. Here, we detail the recent developments and methods allowing exploration of genomic, epigenomic, transcriptomic, and fragmentomic layers of 'omics from liquid biopsy, and their integration in a range of applications. We also consider the specific challenges that are posed by the clinical implementation of multi-omic liquid biopsies.

Citing Articles

Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse.

Baumann A, Buribayev Z, Wolkenhauer O, Salybekov A, Wolfien M Epigenomes. 2025; 9(1).

PMID: 39982247 PMC: 11843950. DOI: 10.3390/epigenomes9010005.

Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications.

Si H, Wang P, Long F, Zhong W, Meng Y, Rong Y Mol Cancer. 2024; 23(1):265.

PMID: 39614371 PMC: 11605934. DOI: 10.1186/s12943-024-02178-6.

References

Chabon J, Hamilton E, Kurtz D, Esfahani M, Moding E, Stehr H . Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020; 580(7802):245-251. PMC: 8230734. DOI: 10.1038/s41586-020-2140-0. View

Tkach M, Hego C, Michel M, Darrigues L, Pierga J, Bidard F . Circulating extracellular vesicles provide valuable protein, but not DNA, biomarkers in metastatic breast cancer. J Extracell Biol. 2024; 1(7):e51. PMC: 11080866. DOI: 10.1002/jex2.51. View

Vaisvila R, Ponnaluri V, Sun Z, Langhorst B, Saleh L, Guan S . Enzymatic methyl sequencing detects DNA methylation at single-base resolution from picograms of DNA. Genome Res. 2021; 31(7):1280-1289. PMC: 8256858. DOI: 10.1101/gr.266551.120. View

Kim S, Jeong S, Lee W, Jeon Y, Kim Y, Park S . Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection. Exp Mol Med. 2023; 55(11):2445-2460. PMC: 10689759. DOI: 10.1038/s12276-023-01119-5. View

Reggiardo R, Maroli S, Peddu V, Davidson A, Hill A, LaMontagne E . Profiling of repetitive RNA sequences in the blood plasma of patients with cancer. Nat Biomed Eng. 2023; 7(12):1627-1635. PMC: 10727983. DOI: 10.1038/s41551-023-01081-7. View

Meddeb R, Pisareva E, Thierry A . Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin Chem. 2019; 65(5):623-633. DOI: 10.1373/clinchem.2018.298323. View

Lo Y, Chan K, Sun H, Chen E, Jiang P, Lun F . Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010; 2(61):61ra91. DOI: 10.1126/scitranslmed.3001720. View

Wan J, Heider K, Gale D, Murphy S, Fisher E, Mouliere F . ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci Transl Med. 2020; 12(548). DOI: 10.1126/scitranslmed.aaz8084. View

Vagner T, Spinelli C, Minciacchi V, Balaj L, Zandian M, Conley A . Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018; 7(1):1505403. PMC: 6084494. DOI: 10.1080/20013078.2018.1505403. View

10.

Bie F, Wang Z, Li Y, Guo W, Hong Y, Han T . Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization. Nat Commun. 2023; 14(1):6042. PMC: 10533817. DOI: 10.1038/s41467-023-41774-w. View

11.

Afflerbach A, Rohrandt C, Brandl B, Sonksen M, Hench J, Frank S . Classification of Brain Tumors by Nanopore Sequencing of Cell-Free DNA from Cerebrospinal Fluid. Clin Chem. 2023; 70(1):250-260. DOI: 10.1093/clinchem/hvad115. View

12.

Ortega-Franco A, Darlington E, Greystoke A, Krebs M . TARGET National: A UK-wide Liquid-based Molecular Profiling Programme: On Behalf of the TARGET National Consortium. Clin Oncol (R Coll Radiol). 2022; 35(1):33-37. DOI: 10.1016/j.clon.2022.10.005. View

13.

La Verde M, De Falco L, Torella A, Savarese G, Savarese P, Ruggiero R . Performance of cell-free DNA sequencing-based non-invasive prenatal testing: experience on 36,456 singleton and multiple pregnancies. BMC Med Genomics. 2021; 14(1):93. PMC: 8011149. DOI: 10.1186/s12920-021-00941-y. View

14.

Ziller M, Gu H, Muller F, Donaghey J, Tsai L, Kohlbacher O . Charting a dynamic DNA methylation landscape of the human genome. Nature. 2013; 500(7463):477-81. PMC: 3821869. DOI: 10.1038/nature12433. View

15.

McKiernan J, Donovan M, ONeill V, Bentink S, Noerholm M, Belzer S . A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016; 2(7):882-9. DOI: 10.1001/jamaoncol.2016.0097. View

16.

Abbosh C, Frankell A, Harrison T, Kisistok J, Garnett A, Johnson L . Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023; 616(7957):553-562. PMC: 7614605. DOI: 10.1038/s41586-023-05776-4. View

17.

Rothwell D, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E . Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019; 25(5):738-743. DOI: 10.1038/s41591-019-0380-z. View

18.

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

19.

Li M, Zeringer E, Barta T, Schageman J, Cheng A, Vlassov A . Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1652). PMC: 4142023. DOI: 10.1098/rstb.2013.0502. View

20.

Klein E, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D . Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32(9):1167-1177. DOI: 10.1016/j.annonc.2021.05.806. View